Tele: 561.316.3330

Breaking Medical Device Industry News

Saturday, October 23, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeiSTAR Medical SA
HomeiSTAR Medical SA

iSTAR Medical SA

Positive Outcomes for iSTAR Medical’s MIGS MINIject

The final two-year data from the STAR-I trial and the six-month follow-up data from the STAR-II European trial, which are comprised in the pooled analysis, will both be presented at the upcoming European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4. The six-month primary endpoint results from the STAR-II trial of MINIject have recently been published in the peer-reviewed Journal of Glaucoma, the official publication of the World Glaucoma Association.

iSTAR Medical MIGS Device Studies: Highly Promising in Glaucoma Patients

The two-year final outcomes from STAR-I trial and six-month results from its European trial STAR-II have been accepted for presentation at the European Glaucoma Society meeting, now postponed to December 2020 following the Covid-19 pandemic.

iSTAR Medical MINIject

Company reports The STAR-I trial demonstrated that the implantation of MINIject resulted in a mean pressure of 15.0mmHgat 18-months, consistent with results reported at 1 year, and at a level expected to reduce the progression of glaucoma.

STAR-I Trial: iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery

12/19/18: STAR-I trial demonstrated that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6 mmHg at one year.

iSTAR Medical Reports MINIject Delivers Exceptional 6-Month Results in First-in-Human Trial

5/16/18: The results show MINIject to be safe and highly effective in achieving significant intraocular pressure (IOP) reduction in glaucoma patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy